Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Goyal RK, et al. Among authors: price gl. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):699-710. doi: 10.1080/14737167.2020.1804871. Epub 2020 Sep 14. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32755262
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL, Sudharshan L, Ryan P, Rajkumar J, Sheffield KM, Nash Smyth E, Morato Guimaraes C, Rybowski S, Cuyun Carter G, Gathirua-Mwangi WG, Huang YJ. Price GL, et al. Curr Med Res Opin. 2022 Aug;38(8):1319-1331. doi: 10.1080/03007995.2022.2073122. Epub 2022 May 13. Curr Med Res Opin. 2022. PMID: 35535675
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW Jr. Kaufman PA, et al. Among authors: price gl. Oncologist. 2020 Feb;25(2):e243-e251. doi: 10.1634/theoncologist.2019-0551. Epub 2019 Oct 24. Oncologist. 2020. PMID: 32043763 Free PMC article. Clinical Trial.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Tolaney SM, et al. Among authors: price gl. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Lancet Oncol. 2020. PMID: 32353342 Clinical Trial.
25 results